Apellis (Waltham, MA) is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of severe asthma and chronic obstructive pulmonary disease (COPD). It has a second program aimed at protecting red blood cells against immune destruction. Apellis had an IPO in November 2017 and is now trading as APLS.
Apellis
Apellis (Waltham, MA) is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of severe asthma and chronic obstructive pulmonary disease (COPD). It has a second program aimed at protecting red blood cells against immune destruction. Apellis had an IPO in November 2017 and is now trading as APLS.
